Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. - Wikidata - wikimedia - TriplyDB

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

http://www.wikidata.org/entity/Q34572620

about

Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics HDL-apoA-I exchange: rapid detection and association with atherosclerosis Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages.Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes Niacin: another look at an underutilized lipid-lowering medication.A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation.High density lipoprotein: it's not just about lipid transport anymore The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan - a cross-sectional study Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice.HDL dysfunction in diabetes: causes and possible treatments.Novel biological functions of high-density lipoprotein cholesterol Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.Advanced glycation end products acutely impair ca(2+) signaling in bovine aortic endothelial cells.Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients.Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle.Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.High density lipoprotein: a therapeutic target in type 2 diabetes.Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease HDL and cholesterol: life after the divorce?HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.Biomarkers associated with high-density lipoproteins in atherosclerotic kidney disease.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation.The causes and consequences of low levels of high density lipoproteins in patients with diabetes.Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus.Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation.The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.Stimulation of phagocyte adhesion to endothelial cells by modified VLDL and HDL requires scavenger receptor BI.The apolipoprotein A-I mimetic peptide, D-4F, restrains neointimal formation through heme oxygenase-1 up-regulation.Pharmacological Intervention to Modulate HDL: What Do We Target?Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction.Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity High Density Lipoprotein: Assembly, Structure, Cargo, and Functions

P2860

Q26774903-A0F0EF0E-9884-43B3-8C80-AC79ACD8CD3C Q28535779-1F793C66-AFE2-490D-8A1C-30A744BFC41F Q30431517-BDB4604C-5469-471F-8BE2-C5175FFABC08 Q33643266-52572E0B-3C28-4339-B29D-8855EC272651 Q34255686-DA33BDAE-A4DB-4934-A677-D7DCB011E7C0 Q34498293-11E8F0B4-F37B-4BCF-8FC9-FEF837E86BCE Q34565254-0BBD5602-C70B-4930-90C0-72A996DB00D3 Q35008066-644EDA3A-200E-42CC-9022-DC62E4A5CC65 Q35626858-2013CF9D-5B43-4A0E-94D8-3A9196332E8C Q35747737-E5259118-40C7-4AFA-8123-F759904F8248 Q35904110-64B63B52-46C0-4314-98B5-2634F7BBECA2 Q36406480-6115212B-A71D-4A0E-8A8F-0F053D6B39CE Q36496865-EEAE5B59-8C53-42CB-B3CC-93144D9EEEA3 Q36671087-90B99667-1817-46CD-850D-F7ADEE43B5AD Q36782743-1F79B7CF-2470-44D5-BDE1-009C66EFB507 Q36842237-8956F9E1-6BEE-4A70-B928-2C6D7C913F3C Q37251396-12E05CCD-E05C-4348-B5E2-903CD3823785 Q37264429-D1ACA489-90DA-48A2-959D-F6438F5BD340 Q37267277-5082EFA0-0416-46D2-AB3D-FBF38D83FA08 Q37305341-B6AD79D0-779C-4348-A09C-1CCEF268BC55 Q37590250-57A62301-8648-4D46-B945-8EAB990FD8BC Q37838234-0E8116D2-E50F-4EE3-B74D-BCBF740C3804 Q38111810-AC4ADC74-1AF6-4096-B65C-0109BC68303A Q38139862-D50ED9B0-C982-4987-80C7-665C3804CEA8 Q38460480-A863C7DA-F4CF-469C-85FF-BB8CFCAAAD67 Q41908048-DAE0B142-9C59-4E4B-9D01-D5039DFB2E5C Q42376634-2E469D6A-CC69-460B-8DB5-89920074A96B Q42773416-207FDA21-081D-4708-8C7F-5550798E1F39 Q43714433-A52A7BFB-8053-4D4F-AF1D-C88AF145667E Q44188060-39803FF5-8D16-4E7A-B522-38EB046C80D9 Q44819479-FBECF4C9-D3A7-4904-8671-85B64288FB66 Q44926429-798E1FC6-F88F-4361-95AD-54F59B0A656A Q47141307-E43F9D75-3322-43DF-ACE2-931770AED2C6 Q49554117-1E0BA407-A843-4454-98CC-4BACD3117AD9 Q50097160-E503DB44-6833-42DF-8187-F168A07A8AAC Q51334798-83736FBF-001A-4210-82B6-DF33978949EE Q53099325-693E6524-3197-4D4D-8457-6EE7E0B7CABC Q56934006-149769BF-E307-4CE4-9D94-BE8DEB04FE01 Q58991979-7E996E3D-E6FA-4A71-BBF2-87FAA38D413D

P2860

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

http://www.wikidata.org/entity/Q34572620

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@ast

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@en

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@nl

type

label

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@ast

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@en

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@nl

prefLabel

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@ast

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@en

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@nl

P1433

Q34572620-C13BE97A-3166-4E01-A7D6-D051BC31C2C6

P1476

Q34572620-2123C219-7EEA-4223-9739-22F5CD52EC74

P2093

Q34572620-05DE667B-285D-4F69-AC22-D67D5B20CE8D

Q34572620-0B3B61BE-7362-4682-83BB-158F09FF8605

Q34572620-10C27378-DE57-4258-AC96-957B04B475AF

Q34572620-3092AA30-E2BA-4AA2-90C3-5CF4738C4245

Q34572620-3E087842-22B7-494B-9761-E38CDDB2CB6A

Q34572620-56E5357E-E456-44B5-B813-CE81F3D8FD84

Q34572620-65516A16-150E-4314-A19F-19140DB37987

Q34572620-7668753F-CE83-46EF-B464-E7AF2561DCCA

Q34572620-EF06FFD0-41C2-43E3-8092-3AD37ACE17B7

Q34572620-F2E8B96F-549F-4DA2-92F7-901B84D266E9

P2860

Q34572620-0B6D960F-A0F7-429C-A566-AD7A22836D2D

Q34572620-0F1C1694-3E0D-4C8B-A8CF-0C3D639606A2

Q34572620-14173A54-1396-41E9-BCD5-78E005A3AC6F

Q34572620-1DCF4C68-5830-4D14-B0BF-7A1C7E217270

Q34572620-2B26E2E4-7D87-44C8-B89A-F20D04130629

Q34572620-34CCFCE1-5AA4-44D0-8F7C-42A36B49F3D0

Q34572620-3CDB919E-7BF9-4E56-8073-AC4924ED502F

Q34572620-5AB87045-AC93-4A32-A7F3-A81CF7135BF7

Q34572620-6138845D-BD05-47F9-B6FA-FEEE30FF27C7

Q34572620-69DB5B73-EA41-421C-98F9-762AAA3BDA2E

P304

Q34572620-CB2DD62D-932B-4A1C-A88E-3151D9F88BFD

P31

Q34572620-5408744B-CD0F-42FB-B7F1-9F38310F9478

P356

Q34572620-A080FE03-F618-4BB7-8423-CA3F17B93098

P407

Q34572620-AE1CE48B-54AA-490D-842A-3CC48DC7ABF1

P433

Q34572620-3DA8CE42-A09D-46C6-A07B-C1106A3CC966

P478

Q34572620-6AFBDFA4-2259-4860-9DC4-294698320C45

P50

Q34572620-25628F48-6A71-4472-892B-68FAD04077A4

Q34572620-3BD3231C-20A5-4123-9B3A-0703B79BB0C0

Q34572620-8FA04F1A-7FB2-4099-A2AD-8325E13952D4

Q34572620-F4D8043C-92A8-466C-86F3-57CA737ECEDD

P577

Q34572620-4CA69BFB-B118-4F06-B3E7-6308DB3D1FB8

P5875

Q34572620-ED1EF37C-A636-43BD-BFA7-1A7864B14138

P698

Q34572620-A065350B-091A-4362-A0A4-7382F0202744

P932

Q34572620-ECCB30FE-50FB-45E7-AA83-E21D8702F41E

P356

ATVBAHA.109.201715

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

@en

P2093

David J Bonnet

http://www.w3.org/2001/XMLSchema#string

Estelle Nobécourt

http://www.w3.org/2001/XMLSchema#string

Fatiha Tabet

http://www.w3.org/2001/XMLSchema#string

Gregory J Dusting

http://www.w3.org/2001/XMLSchema#string

Kerry-Anne Rye

http://www.w3.org/2001/XMLSchema#string

Linda K Curtiss

http://www.w3.org/2001/XMLSchema#string

Ling Yan

http://www.w3.org/2001/XMLSchema#string

Philip J Barter

http://www.w3.org/2001/XMLSchema#string

Rajesh Puranik

http://www.w3.org/2001/XMLSchema#string

Shisan Bao

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemistry and molecular cell biology of diabetic complications

Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Regulation of intercellular adhesion molecule-1 (CD54) gene expression.

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Why is HDL functionally deficient in type 2 diabetes?

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia

Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells.

P304

766-772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.109.201715

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Michael Jonathan Davies

Bronwyn E Brown

P577

2010-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41173872

http://www.w3.org/2001/XMLSchema#string

P698

20110571

http://www.w3.org/2001/XMLSchema#string

P932

3038672

http://www.w3.org/2001/XMLSchema#string